Thanks, Pfizer: Mylan execs in line for $71M-plus golden parachutes in Upjohn merger

When Mylan and Pfizer's Upjohn business trumpeted their pending merger in July, it marked a major coup for the generics maker's shareholders after a rough couple of years. Turns out the deal wasn't just profitable for investors––it could also be a big score for Mylan's C-suite.